Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Passes Above 200-Day Moving Average – Here’s Why

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.97 and traded as high as $2.75. Sonoma Pharmaceuticals shares last traded at $2.64, with a volume of 60,402 shares.

Sonoma Pharmaceuticals Stock Down 1.5 %

The business’s 50 day simple moving average is $2.76 and its 200 day simple moving average is $1.98. The company has a market capitalization of $3.53 million, a PE ratio of -0.53 and a beta of 1.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.